Sociedad Canadiense de Hipertensión | 06 AGO 03
Recomendaciones para el tratamiento de la hipertensión arterial
Este resumen destaca las recomendaciones para el manejo de la hipertensión, las novedades y los conceptos anteriores aun vigentes.
Autor: Sociedad Canadiense de Hipertensión Fuente: Evidence Based Recommendations Task Force of the Canadian Hypertension. Education Program Robarts Research Institute. London, Ontario, Canada.
1) The Canadian Hypertension Recommendations Working Group. The 2001 Canadian hypertension recommendations. What is new and what is old but still important. Can J Cardiol 2002; 18(6): 591-603.

2) World Health Organization. The World Health Report 2002.

3) Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 1997; 10(10 Pt 1): 1097-102.

4) Zarnke KB, Campbell NRC, McAlister F, Levine M for the Canadian Hypertension Recommendations Working Group. A novel process for updating recommendations for managing hypertension: rationale and methods. Can J Cardiol 2000:16:1094-102.

5) The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981-97.

6) Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GLR, et al for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-92.

7) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265 (24): 3255-64.

8) Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. The Life Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311): 995-1003.

9) Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H, et al, for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-9.

10) Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al, for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-60.

11) Vasan RS, Larson, MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, Levy D. Impact  of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345:1291-7.

12) Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction guide. BMJ 2000; 320:709-10.

13) Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351(9118): 1755-62.

14) Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342 (3): 45-53.

15) Vasan RS, Beiser A, Seshadri S, Larson M, Kannel WB, D'Agostino RB, Levy, D. Residual Lifetime Risk for Developing Hypertension in Middle-aged Women and Men. JAMA. 2002; 287:1003-1010.


Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí